GLP-1 Medicines Registered in Czechia: A Factual Comparison

Search for a comparison of these medicines and you will find a great deal of marketing and very little balance. This article sets out what is registered in Czechia, what each product is approved to treat, what the trials measured, and what the known risks are. One conclusion belongs at the top, because everything else follows from it: there is no universally best medicine in this class, and the choice is a clinical decision rather than a consumer one.

Which medicines are registered in Czechia

All of the products below are prescription-only. Full summaries of product characteristics are available through the SÚKL database.

Two clarifications save a lot of disappointment. First, Ozempic and Rybelsus are not weight-loss medicines. Both are authorised solely for type 2 diabetes, and the Ozempic EPAR describes weight loss only as an effect observed in trials, not an indication. In Czechia, the eRecept system requires a recorded type 1 or type 2 diabetes diagnosis to prescribe the 0.25 mg and 1 mg presentations (ePreskripce, in Czech); restrictions on the 0.5 mg presentation were lifted in November 2025 (ePreskripce, in Czech), which does not make it a weight-loss medicine – it remains authorised for type 2 diabetes only.

Second, the same substance can appear in different products at different doses for different purposes, which is why semaglutide appears three times above under three separate approvals.

Indications follow the European public assessment reports for Wegovy, Mounjaro and Saxenda, the last of which also covers adolescents.

What the trials measured

There is also evidence beyond weight. In the SELECT trial, semaglutide reduced major cardiovascular events in people with overweight or obesity and established cardiovascular disease. That is a different question from weight loss, and it matters for some patients and not others.

Why you cannot rank these from a table

The numbers above look directly comparable. They are not, and treating them that way is the single most common mistake in this area.

• These are separate trials. Different populations, entry criteria, designs and periods. Results from one cannot be placed head-to-head against another as if they were a race.
• They are averages. Individual response varies enormously. Plenty of people lose more on an "average weaker" option than on an "average stronger" one.
• Everyone changed their habits too. Participants also adjusted diet and physical activity. The medicine supported that change rather than replacing it.
• Weight is not the only outcome. Cardiovascular risk, blood glucose control, tolerability and existing conditions all count in a real clinical decision.

There is also the question of what happens afterwards. Obesity is a chronic condition, and weight commonly returns when treatment stops: in SURMOUNT-4, participants regained a substantial share of the weight they had lost after discontinuing treatment. Any honest comparison has to include the long-term plan, not just the peak number.

Side effects and contraindications

The whole class shares a broadly similar risk profile, dominated by gastrointestinal effects. For the weight-management products, nausea, vomiting, diarrhoea and constipation are each listed as affecting more than one in ten people in the assessment reports for Wegovy, Mounjaro and Saxenda. Frequencies differ between products, so the summary of product characteristics for the specific product is what counts: the Ozempic EPAR, for instance, lists diarrhoea, vomiting and nausea at that frequency but not constipation. These effects are typically worst while the dose is being increased and often ease with time.

Less common but more serious risks include pancreatitis, gallbladder problems and dehydration. These medicines are not to be used in pregnancy or while breastfeeding, and they are not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Some people cannot tolerate treatment at all and stop because of side effects.

None of this can be self-assessed from an article. A doctor always makes the decision, weighing your history, your other medicines and your existing conditions, and the doctor may decline treatment.

Who pays for treatment here

For weight management, this treatment is self-pay for everyone in the Czech Republic. That is not a rule aimed at foreigners: public insurance does not reimburse these medicines for this purpose, so a Czech citizen and a foreign resident pay exactly the same. Commercial policies sold to foreign nationals generally describe their scope as comparable to public health insurance, which reimburses these medicines for nobody, so they usually do not pay either (PVZP, in Czech); your pojistné podmínky, the terms attached to your own policy, are what settle it. Our guide to health insurance and weight-loss medication goes through this in detail.

There are two separate costs: the medical service, and the medicine at the pharmacy. With GoOn you pay only for consultations, at the same price Czech patients pay.

The medicine is paid separately at the pharmacy and runs roughly 2,000 to 6,000 CZK per month, with starting and titration doses at the lower end of that band and maintenance doses towards the upper end, depending on the product and dose. Read it as orientation rather than a quote, because pharmacies set their own retail prices and only the pharmacy can confirm the final figure. The full breakdown is in our article on what treatment costs in Czechia.

So which one is best?

The honest answer is that the question is framed wrongly. There is no universally best option, and a doctor choosing between them weighs at least four things at once:

• Your diagnosis and other conditions. Type 2 diabetes changes the calculation entirely, as does established cardiovascular disease.
• Tolerability. This is individual and cannot be predicted in advance. Sometimes the answer is a dose adjustment rather than a different product.
• Practicalities. A weekly injection, a daily injection and a daily tablet are not equivalent in daily life, and pharmacy availability fluctuates.
• Cost. Monthly cost differs meaningfully between products and doses.

Anyone confidently naming one product as simply the best, without knowing your medical history, is selling rather than advising.

How the pathway works in Czechia

You do not choose the medicine; you get assessed and then discuss the options. In practice that means a consultation in which a doctor reviews your history, your BMI, your current medicines and your goals. If treatment is appropriate, the doctor issues a Czech eRecept and you collect the medicine yourself at any Czech pharmacy. Under the Medicines Act (Act No. 378/2007 Sb.), distance selling by Czech pharmacies covers over-the-counter products only, so mail order of prescription-only medicines is illegal in the Czech Republic (SÚKL) and collection in person is the only route. The warning signs are set out in our guide to illegal online pharmacies.

You do not need a registered Czech GP for this, which matters given that 554,000 people here have no GP, 65% of them foreign nationals, on Health Ministry figures published in July 2025. If you would like to know where you stand, you can complete the questionnaire and speak to a doctor online in English, at the same price Czech patients pay. You can also check your BMI beforehand.

Frequently asked questions

What is the difference between Wegovy and Mounjaro?

Wegovy contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors. Both are weekly injections authorised for weight management, and Mounjaro additionally carries an indication for type 2 diabetes. The weight-loss trials cited above were run separately and cannot be stacked against each other, though one head-to-head trial does exist: in SURMOUNT-5 tirzepatide produced a greater average reduction than semaglutide, in a trial that was open-label and funded by the tirzepatide manufacturer, and in which 5.6% of semaglutide and 2.7% of tirzepatide participants stopped because of gastrointestinal effects.

Which GLP-1 medicine is the most effective?

No single product is best for everyone. The highest average weight reduction in the trials above was seen with tirzepatide, but those trials were not run against each other, individual response varies widely, and effectiveness is only one of several factors a doctor weighs alongside diagnosis, tolerability, availability and cost.

Is Ozempic a weight-loss medicine?

No. It is authorised for type 2 diabetes only, and in Czechia the eRecept system requires a recorded type 1 or type 2 diabetes diagnosis to prescribe the 0.25 mg and 1 mg presentations (ePreskripce, in Czech). Restrictions on the 0.5 mg presentation were lifted in November 2025 (ePreskripce, in Czech), which changes nothing about the authorisation. Weight loss was observed in trials as an effect, but it is not an approved indication, and other products carry the weight-management authorisation instead.

Are these medicines covered by Czech health insurance?

Not for weight management. Public insurance does not reimburse them for this purpose, so treatment is self-pay for Czech citizens and foreign residents alike, at the same price. Commercial policies sold to foreign nationals generally describe their scope as comparable to public health insurance, so they usually do not pay either; the terms attached to your own policy are what settle it, and we work through the detail in Czech health insurance and weight-loss medication.

Do I need a Czech GP to be assessed?

No. Registration with a GP is not mandatory in Czechia and is not needed for a telemedicine consultation, which we cover in obesity treatment without a Czech GP. A licensed Czech doctor can assess you in English and will decide whether treatment is appropriate, which includes the possibility of declining it.